Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation

Inclusion Criteria: * Male or female patients 18 years old or older as of visit one. * If female is not trying to conserve, not lactating, and has a negative serum pregnancy test and use an acceptable method of contraception or be at least one year post-menopausal or surgically sterile. * Able to provide written informed consent. * First time liver transplant recipient. * Primary, single organ recipient (deceased donor \<65 years old). * receive regular long-term HBIG prophylaxis with stabilized HBIG dosage and administration intervals. * Have negative quantifiable HBV-DNA and HBsAg results prior to dosing at visit 2. * Following the last IV administration of HBIG, have a baseline serum anti-HBs level of \>150 IU/ML prior to dosing at visit 2. Exclusion Criteria * Positive HCV or HIV test results. * Unexplained elevated liver function tests. * Serum creatinine level \>2.0 times the upper limit of normal. * life expectancy \<6 months. * liver transplantation with ongoing acute rejection episode. Donor liver that was from a hepatitis Bor C positive donor. Underwent a liver transplant \<12 months prior to visit 1. * Know history of cancer, suspected cancer, or cancer therapy within 12 months. * History of autoimmune disease. * History/current evidence of coagulation disorder, severe cardiac disease, unhealed gastric or duodenal ulcer, or other significant disease. * Evidence of any other unresolved infection and any unresolved opportunistic infection requiring treatment. * Known immunoglobulin A deficiency. * History of use of immunosupressive or immunomodulatory drug within 3 month prior to visit 1. (except low dose glucocorticoid therapy, \<10 mg of prednisone or equivalent per day.) * received and investigational drug 30 days prior to visit 1. * use of plasma preparations or other immunoglobulins during the study. * Know intolerance to proteins of human origin, immunoglobulin, or comparable products. * Evidence of alcohol and/or drug abuse within 6 month of visit 2 or inability/unwillingness to abstain from alcohol for the duration of the study.